Dienogest

- ▴ The progestogen dienogest exhibits highly selective binding to the progesterone receptor. It has high progestational and significant antiandrogenic activity, but only moderate antigonadotrophic activity. - ▴ Dienogest inhibits ovulation, produces secretory transformation of the endometrium and has antiproliferative effects. - ▴ Oral dienogest 2 mg/day plus ethinylestradiol 30 μg/day provides effective contraception (Pearl Index approximately 0.2). Cycle stability is good during long term use of this combination; irregular vaginal bleeding was evident in 6% of women after 12 months’ use. - ▴ Androgenic symptoms (including hirsutism, seborrhoea, alopecia, acne vulgaris and hair and skin greasiness) improved in women treated with dienogest plus ethinylestradiol. - ▴ The adverse events associated with dienogest are typical of those expected of a progestogen. The drug does not produce androgenic adverse effects and has little clinically significant effect on metabolic, lipid and haemostatic parameters. Similar content being viewed by others

Oettel M, Carol W, Elger W, et al. A 19-norprogestin without 17α-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today 1995 Oct–Nov; 31: 517–36 Oettel M, Bervoas-Martin S, Elger W, et al. A 19-norprogestin without a 17α-ethinyl group I: dienogest from a pharmacokinetic point of view. Drugs Today 1995 Oct–Nov; 31: 499–516 Juchem M, Schaffrath M, Pollow K, et al. Dienogest: Bindungsstudien an verschiedenen Rezeptor- und Serumproteinen. In: Teichmann AT, editor. Dienogest: Präklinik und Klinik eines Gestagens. 2nd ed. Berlin: Walter de Gruyter, 1995: 119–33 Stolzner W, Kurischko A, Freund H, et al. Progestagenic and antigonadotrophic activities of STS 557. Exp Clin Endocrinol 1983 Feb;81: 115–21 Oettel M, Kurischko A. STS 557, a new orally active progestin with antiprogestational and contragestational properties in rabbits. Contraception 1980 Jan; 21: 61–9 Böhm W, Hempel E, Carlsohn G. The problematic nature of dosage transformation determination of gestagens [in German]. In: Stech D, Carol W, editors. Proceedings of the IIIrd Jenaer Symposium zur hormonalen Kontrazeption; 1984 Apr 10–11; Jena, Germany. Jena: Friedrich-Schiller-Universität, 1985: 109–13 Katsuki Y, Sasagawa S, Takano Y, et al. Animal studies on the endocrinological profile of dienogest, a novel synthetic steroid. Drugs Exp Clin Res 1997; 23(2): 45–62 Oettel M, Komor A, Goncharov NP, et al. STS 557 as an interceptive in rodents and baboons. Contraception 1980 May; 21: 537–49 Oettel M, Tkocz H, Löw O, et al. Effects of levonorgestrel and STS 557 on testis in rodents. Endokrinologie 1980 Jul; 76: 13–22 Moore C, Walter F, Klinger G, et al. The influence of dienogest on ovulation in younger women and on chosen endocrinological parameters [in German]. In: Teichmann AT, editor. Dienogest: Präklinik und Klinik eines Gestagens. 2nd ed. Berlin: Walter de Gruyter, 1995: 161–9 Schleuβner E, Michels W, Bethge S, et al. Die Wirkung von Dienogest auf die hypothalamisch-hypophysäre Achse: Ergebnisse einer Pilotstudie. In: Teichmann AT, editor. Dienogest: Präklinik und Klinik eines Gestagens. 2nd ed. Berlin: Walter de Gruyter, 1995: 171–9 Spona J, Feichtinger W, Kindermann C, et al. Modulation of ovarian function by an oral contraceptive containing 30μg ethinyl estradiol in combination with 2.00mg dienogest. Contraception 1997 Sep; 56: 185–91 Köhler G, Göretzlehner G, Rudolf K, et al. The effect of a single midcycle administration of 0.5 or 2.0 mg dienogest (17α-cyanomethyl-17β-hydroxy-estra-4,9-dien-3-one) on pituitary and ovarian function: investigation for the use as a postcoital contraceptive. Exp Clin Endocrinol 1984 Dec; 84: 299–304 Oettel M, Elger W, Ernst M, et al. Experimentelle Endokrinpharmakologie von Dienogest. In: Teichmann AT, editor. Dienogest: Präklinik und Klinik eines Gestagens. 2nd ed. Berlin: Walter de Gruyter, 1995: 11–21 Oettel M, Carol W, Gräser T, et al. The influence of an ethinyl-estradiol-dienogest combination on serum androgen concentrations. Zentralbl Gynakol 1997; 119(12): 597–606 Hagen H, Hagen A, Lehnert W, et al. The clinical recording of anti-androgenic effects of dienogest [in German]. In: Teichmann AT, editor. Dienogest: Präklinik und Klinik eines Gestagens. 2nd ed. Berlin: Walter de Gruyter, 1995: 223–30 Coll i Capdevila C. Clinical experience with Valette® [abstract no. 101]. Eur J Contracept Reprod Health Care 1998 June; 3 Suppl. 1: 77 Koch M. Influence of STS 557 on the mitotic activity in the endometrium of ovariectomized mice and comparison with the effects of progesterone and levonorgestrel. Exp Clin Endocrinol 1984 May; 83: 310–4 Koch M, Stracke R, Peschke T. Effects of antifertility estrogens and progestins on the endometrial surface of early pregnant rats: a scanning electron microscopic study. Exp Clin Endocrinol 1985 Apr; 85: 138–46 Katsuki Y, Shibutani Y, Aoki D, et al. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins. Cancer 1997 Jan 1; 79: 169–76 Lippert TH, Seeger H, Mueck AO, et al. Effect of estradiol, progesterone, and progestogens on calcium influx in cell cultures of human vessels. Menopause 1996; 3(1): 33–7 Strecke J, Stolzner W, Freund H, et al. Interceptive activities of STS 557 in rabbits, mice and rats. Exp Clin Endocrinol 1983 Feb; 81: 122–36 Schubert K, Hobe G, Kauffman G, et al. Synthesis, effects, and metabolism of the progestagen and potential interceptive dienogest. Presented at the International Symposium on the Chemistry of Natural Products; 1984 Jul 9–14; Poznan, Poland. In: Zalewski RI, Skolik JJ, editors. Natural products chemistry. Amsterdam: Elsevier Science Publishers, 1985: 143–58 Komor A, Goncharov NP, Schubert K, et al. STS 557 as an interceptive in baboons. Exp Clin Endocrinol 1983 Feb; 81: 217–21 Komor A, Goncharov NP, Oettel M. Further report on the interceptive STS 557 in baboons. Endokrinologie 1982 Jul; 79: 428–30 Chaudhary J, Sharma RK, Majumdar SS, et al. Effect of STS-557 (17 alpha-cyanomethyl 17β-hydroxy-estra-4,9 (10)-dien-3-one) on blood hormone levels, the testis, accessory sex organs and fertility of rats. Int J Andrology 1990; 13(5): 398–407 Freund H, Hesse G, Oettel M. Effect of STS 557 on semen composition, fertility and sexual behaviour of male rabbits. Contraception 1980 Jun; 21: 641–50 Majumdar SS, Chaudhary J, Sharma RK, et al. Contraceptive potentiality of STS-557: a feasibility study in male bonnet monkey (Macaca radiata). Contraception 1990 Jun; 41: 641–53 Oettel M, Freund H, Hesse G, et al. Inhibition of male fertility by STS 557. Exp Clin Endocrinol 1983 Feb; 81: 137–45 Sharma RK, Das R. Effects of STS-557 and 20 AET-1 on sperm functions and serum level of testosterone in bonnet monkey (Macaca radiata). Contraception 1992 May; 45: 483–91 Srivastava A, Maikhuri JP, Setty BS. Evaluation of STS-557 as an oral contraceptive in male rat. Contraception 1987 Aug; 36: 253–72 Hobe G, Hillesheim HG, Schumann W, et al. Studies on pharmacokinetics of STS 557 in animal species and man. Exp Clin Endocrinol 1983 Feb; 81: 158–67 Carol W, Klinger G, Michels W, et al. Studies on the pharmacokinetics of contraceptive steroids under steady-state conditions [in German]. Zentralbl Gynakol 1991; 113: 1298–303 Dittgen M, Gräser T, Kaufmann G, et al. Hot spin mixing — a new technology to manufacture solid dispersions. Part 2: Dienogest. Pharmazie 1995; 50(6): 438–9 Böcker R, Kleingeist B. Der Einfluβ von Dienogest auf das humane Cytochrom P450-Enzymsystem in vitro. In: Teichmann AT, editor. Dienogest: Präklinik und Klinik eines Gestagens. 2nd ed. Berlin: Walter de Gruyter, 1995: 141–7 Balogh A, Lautenschlager MT, Hippius M, et al. The influence of ethinylestradiol (EE) containing contraceptives in combination with dienogest (DNG) or levonorgestrel (LNG) on cytochrome P450IIIA4 in vivo [abstract]. Eur J Endocrinol 1994 Jun; 130 Suppl. 2: 166 Balogh A, Liewald T, Liewald S, et al. The influence of a new sexual steroid — dienogest on the metabolism of caffeine and metamizol [in German]. Zentralbl Gynakol 1990; 112(12): 735–46 Moore C, Walter F, Mellinger U, et al. Multicentre study on contraceptive safety, cycle control and tolerance of MP 2000 Micropille: an interim report [in German]. In: Teichmann AT, editor. Dienogest: Präklinik und Klinik eines Gestagens. 2nd ed. Berlin: Walter de Gruyter, 1995: 203–12 Llewellyn-Jones D, editor. Fundamentals of obstetrics and gynaecology. Volume 2. Gynaecology. 5th ed. London: Faber and Faber Ltd., 1990 Köhler VG, Canzler E, Lembke S, et al. Postcoital contraception with dienogest [in German]. Zentralbl Gynakol 1987; 109: 1296–302 Spona J, Feichtinger W, Kindermann C, et al. Clinical profile of Valette® [abstract no. 100]. Eur J ContraceptReprod Health Care 1998 June; 3 Suppl. 1: 77 Köhler G. Die Therapie der Endometriose mit Dienogest: eine Renaissance der Gestagene. In: Teichmann AT, editor. Dienogest: Präklinik und Klinik eines Gestagens. 2nd ed. Berlin: Walter de Gruyter, 1995: 243–51 Heinecke H, Köhler D. Prenatal toxic effects of STS 557. II. Investigation in rabbits: preliminary results. Exp Clin Endocrinol 1983; 81(2): 206–9 Jemilev ZA, Komor A, Strecke J, et al. Chromosomal analysis of baboons and their mothers, following application to mothers of potentially post-ovulation fertility-inhibiting steroids [in German]. Zentralbl Gynakol 1981; 103: 1215–9 Schöneich J, Becker K, Braun R. Investigations on the mutagenic activity of STS 557. Exp Clin Endocrinol 1983 Feb; 81: 210–6 Köhler G, Göretzlehner G, Brachmann K. Lipid metabolism during treatment of endometriosis with the progestin dienogest. Acta Obstet Gynecol Scand 1989 Jul; 68: 633–5 Nikschick S, Köhler G, Männchen E. Carbohydrate metabolism during treatment of endometriosis with the progestin dienogest. Exp Clin Endocrinol 1989 Sep; 94: 211–4 Köhler G, Lembke S, Brachmann K, et al. Routine liver function testing during treatment of endometriosis with the progestin dienogest [in German]. Zentralbl Gynakol 1989; 111: 807–10 Lembke S, Köhler G, Kalmar B, et al. Clinical and paraclinical results with dienogest-combination preparation: the influence on glucose metabolism and voice function [in German]. In: Carol W, Stech D, editors. Proceedings of the IVth Jenaer Symposium zur hormonalen Kontrazeption; 1988 Mar 22–23; Jena, Germany. Jena: Friedrich-Schiller-Universität, 1989: 179–84 Spona J, Feichtinger W, Kindermann C, et al. Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30μg ethinyl estradiol and 2.00 mg dienogest on the hemostatic system. Contraception 1997 Aug; 56: 67–75 Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Foster, R.H., Wilde, M.I. Dienogest. Drugs 56, 825–833 (1998). https://doi.org/10.2165/00003495-199856050-00007 Published: Issue date: DOI: https://doi.org/10.2165/00003495-199856050-00007